CHANDAN Chandan Healthca Q1 FY27 results (Apr–Jun 2026) and concall
Chandan Healthcare reported a strong Q1 FY27, driven by robust growth in its standalone diagnostics segment and aggressive network expansion. The company strategically divested its pharmacy business for ₹16.77 crores to sharpen its focus on higher-margin diagnostics. Management provided an ambitious outlook, targeting over 50% top-line growth for the diagnostic business and aiming for 40% EBITDA margin in the near future, supported by a rapidly expanding franchise model and new comprehensive centers.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 19.1%, net profit up 27.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 110 | 55 | 63 | 68 | 68 −38% | 65 +19% | 76 +21% | 81 +19% |
| EBITDA | 20 | 9 | 10 | 14 | 14 −29% | 12 +33% | 11 +12% | 20 +41% |
| Net profit | 11 | 4 | 6 | 6 | 8 −29% | 5 +8% | 5 −18% | 8 +28% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
